JP2016523260A5 - - Google Patents

Download PDF

Info

Publication number
JP2016523260A5
JP2016523260A5 JP2016521898A JP2016521898A JP2016523260A5 JP 2016523260 A5 JP2016523260 A5 JP 2016523260A5 JP 2016521898 A JP2016521898 A JP 2016521898A JP 2016521898 A JP2016521898 A JP 2016521898A JP 2016523260 A5 JP2016523260 A5 JP 2016523260A5
Authority
JP
Japan
Prior art keywords
pruritus
serlopitant
octahydroisoindol
cyclopent
polymorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016521898A
Other languages
Japanese (ja)
Other versions
JP2016523260A (en
Filing date
Publication date
Priority claimed from US13/925,509 external-priority patent/US8906951B1/en
Application filed filed Critical
Priority claimed from PCT/US2014/043811 external-priority patent/WO2014209962A1/en
Publication of JP2016523260A publication Critical patent/JP2016523260A/en
Publication of JP2016523260A5 publication Critical patent/JP2016523260A5/ja
Ceased legal-status Critical Current

Links

Claims (1)

そう痒の処置を必要としている患者においてそう痒を処置する方法であって、該患者に3-[(3aR,4R,5S,7aS)-5-[(1R)-1-[3,5-ビス(トリフルオロメチル)フェニル]エトキシ]-4-(4-フルオロフェニル)-1,3,3a,4,5,6,7,7a-オクタヒドロイソインドール-2-イル]シクロペンタ-2-エン-1-オン（セルロピタント（serlopitant））またはその薬学的に許容される塩、溶媒和物もしくは多形の治療的有効量を投与する段階を含む、方法。   A method of treating pruritus in a patient in need of pruritus treatment comprising the steps of: 3-[(3aR, 4R, 5S, 7aS) -5-[(1R) -1- [3,5- Bis (trifluoromethyl) phenyl] ethoxy] -4- (4-fluorophenyl) -1,3,3a, 4,5,6,7,7a-octahydroisoindol-2-yl] cyclopent-2-ene Administering a therapeutically effective amount of 1-one (serlopitant) or a pharmaceutically acceptable salt, solvate or polymorph thereof.
JP2016521898A 2013-06-24 2014-06-24 Use of the NK-1 receptor antagonist cellulopitant in pruritus Ceased JP2016523260A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361838784P 2013-06-24 2013-06-24
US61/838,784 2013-06-24
US13/925,509 US8906951B1 (en) 2013-06-24 2013-06-24 Use of NK-1 receptor antagonists in pruritus
US13/925,509 2013-06-24
PCT/US2014/043811 WO2014209962A1 (en) 2013-06-24 2014-06-24 Use of nk-1 receptor antagonist serlopitant in pruritus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019087897A Division JP2019142960A (en) 2013-06-24 2019-05-07 Use of serlopitant as nk-1 receptor antagonist in pruritus

Publications (2)

Publication Number Publication Date
JP2016523260A JP2016523260A (en) 2016-08-08
JP2016523260A5 true JP2016523260A5 (en) 2017-08-03

Family

ID=51230173

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016521898A Ceased JP2016523260A (en) 2013-06-24 2014-06-24 Use of the NK-1 receptor antagonist cellulopitant in pruritus
JP2019087897A Pending JP2019142960A (en) 2013-06-24 2019-05-07 Use of serlopitant as nk-1 receptor antagonist in pruritus

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019087897A Pending JP2019142960A (en) 2013-06-24 2019-05-07 Use of serlopitant as nk-1 receptor antagonist in pruritus

Country Status (13)

Country Link
EP (1) EP3013336A1 (en)
JP (2) JP2016523260A (en)
KR (1) KR20160023692A (en)
CN (1) CN105473138A (en)
AU (2) AU2014302694B2 (en)
BR (1) BR112015031724A2 (en)
CA (1) CA2915474A1 (en)
HK (1) HK1223820A1 (en)
IL (1) IL243189A0 (en)
MX (2) MX366728B (en)
PH (2) PH12015502777A1 (en)
RU (1) RU2666219C2 (en)
WO (1) WO2014209962A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
EP3193830B1 (en) 2014-09-19 2023-11-01 Heron Therapeutics, Inc. Emulson formulations of aprepitant
BR112017018620A2 (en) 2015-03-04 2018-04-17 Vanda Pharmaceuticals Inc. method of administration of tradipitanto, and tradipitanto.
JP6829257B2 (en) * 2016-02-01 2021-02-10 ヘロン セラピューティクス， インコーポレイテッドＨｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Emulsion containing NK-1 receptor antagonist
US9974742B2 (en) 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
JP2019519592A (en) * 2016-06-29 2019-07-11 メンロ セラピューティクス インコーポレイテッド Use of Neurokinin-1 Antagonists to Treat Various Pruritus Conditions
CN111093671A (en) * 2017-09-13 2020-05-01 万达制药公司 Improved treatment of atopic dermatitis with tropiptan
CN111886025A (en) * 2017-11-01 2020-11-03 新加坡国立大学 Use of serotonergic agents for the treatment of virus-induced thrombocytopenia
BR112020015688A8 (en) * 2018-01-31 2022-07-05 Twi Pharmaceuticals Inc TOPICAL FORMULATIONS INCLUDING TOFACITINIB
CN115015440A (en) * 2022-07-08 2022-09-06 江苏杜瑞制药有限公司 Method for detecting naftifine in biological sample
CN117503699A (en) * 2023-12-08 2024-02-06 斯坦德医药研发(江苏)有限公司 Aprepitant oral liquid preparation and preparation method thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100565A1 (en) 2001-09-21 2003-05-29 Boehringer Ingelheim International Gmbh Method for the treatment or prevention of atopic dermatitis
TWI341198B (en) 2004-01-27 2011-05-01 Merck Sharp & Dohme Hydroisoindoline tachykinin receptor antagonists
CN100582093C (en) * 2004-01-27 2010-01-20 默克公司 Hydroisoindoline tachykinin receptor antagonists
AU2006269383A1 (en) 2005-07-11 2007-01-18 Merck Sharp & Dohme Corp. Process for making hydroisoindoline tachykinin receptor antagonists
EP1937264B1 (en) 2005-10-04 2011-06-08 Merck Sharp & Dohme Corp. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
WO2007146224A2 (en) 2006-06-12 2007-12-21 Merck & Co., Inc. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
US20100209496A1 (en) 2006-09-06 2010-08-19 Eleni Dokou Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
US20090270477A1 (en) 2006-11-02 2009-10-29 Kuethe Jeffrey T Polymorphs of a hydroisoindoline tachykinin receptor antagonist
EP2141992A1 (en) 2007-03-29 2010-01-13 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
RU2370265C1 (en) * 2008-03-04 2009-10-20 Лев Давидович Раснецов Gel, possessing anti- inflammatory and antiallergic effect

Similar Documents

Publication Publication Date Title
JP2016523260A5 (en)
JP2016034978A5 (en)
CY1124669T1 (en) ANTI-ESTROGEN DRUGS TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLIOY
JP2014156468A5 (en)
JP2016518337A5 (en)
JP2013519675A5 (en)
JP2016515522A5 (en)
JP2017035491A5 (en) Method and apparatus for treatment of intracranial hemorrhage
CY1118839T1 (en) COVERED PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIBE
JP2016535795A5 (en)
EP3589628A4 (en) Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
EA201790630A1 (en) METHODS OF OBTAINING RIBOSIDS
EP3607950A3 (en) Hepatitis b core protein allosteric modulators
JP2015024998A5 (en)
JP2016539157A5 (en)
JP2013543896A5 (en)
JP2015078220A5 (en)
JP2016515561A5 (en)
JP2011148799A5 (en)
JP2013173781A5 (en)
EA201391485A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
JP2015504870A5 (en)
JP2016522254A5 (en)
HRP20191121T1 (en) Multiple sclerosis treatment
JP2015199738A5 (en)